P/E ratio for Matinas BioPharma (MTNB)
P/E ratio as of May 2024 (TTM): -1.57
According to Matinas BioPharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.57273. At the end of 2022 the company had a P/E ratio of -4.55.
P/E ratio history for Matinas BioPharma from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.55 | -50.5% |
| 2021 | -9.18 | -18.98% |
| 2020 | -11.3 | -30.1% |
| 2019 | -16.2 | 308.76% |
| 2018 | -3.97 | 26.52% |
| 2017 | -3.14 | -52.97% |
| 2016 | -6.67 | 49.02% |
| 2015 | -4.47 | 220.77% |
| 2014 | -1.39 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -4.14 | 163.08% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.